Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Sartorius vz Sector Perform (DPA-AFX) +++ SARTORIUS VZO Aktie +4,02%

ORION CORP B Aktie

 >ORION CORP B Aktienkurs 
83.1 EUR    +2.3%    (TradegateBSX)
Ask: 83.1 EUR / 500 Stück
Bid: 83 EUR / 500 Stück
Tagesumsatz: 90 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ORION CORP B Aktie über LYNX handeln
>ORION CORP B Performance
1 Woche: -3,7%
1 Monat: +1,9%
3 Monate: +13,0%
6 Monate: +16,4%
1 Jahr: +24,8%
laufendes Jahr: +27,2%
>ORION CORP B Aktie
Name:  ORION CORP. B
Land:  Finnland
Sektor:  Gesundheit
ISIN/ Wkn:  FI0009014377 / A0J3QM
Symbol/ Ticker:  OFK (Frankfurt)
Kürzel:  FRA:OFK, ETR:OFK, OFK:GR
Index:  -
Profil:  Orion Oyj Class B represents the publicly traded Class B shares of Orion Oyj, a globally operating Finnish pharmaceutical company founded in 1917 and headquartered in Espoo, Finland. The company develops, manufactures, and markets human and veterinar..
>Volltext..
Marktkapitalisierung:  11327.44 Mio. EUR
Unternehmenswert:  11329.94 Mio. EUR
Umsatz:  2087.38 Mio. EUR
EBITDA:  810.89 Mio. EUR
Nettogewinn:  595.69 Mio. EUR
Gewinn je Aktie:  4.23 EUR
Schulden:  134.64 Mio. EUR
Liquide Mittel:  132.1 Mio. EUR
Operativer Cashflow:  478.6 Mio. EUR
Bargeldquote:  0.29
Umsatzwachstum:  22.6%
Gewinnwachstum:  55.32%
Dividende je Aktie:  1.72 EUR
Dividendenrendite:  2.13%
Dividendenschätzung:  2.22%
Div. Historie:  25.03.26 - 0.9€
15.10.25 - 0.82€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ORION CORP B, ORION CORP, ORION OYJ, ORION CORPORATION, ORION PHARMA
Letzte Datenerhebung:  06.10.26
>ORION CORP B Kennzahlen
Aktien/ Unternehmen:
Aktien: 109.59 Mio. St.
Frei handelbar: 97.2%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 4029
Umsatz/Mitarb.: 0.49 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -4.41%
Bewertung:
KGV: 19.42
KGV lG: 20.04
KUV: 5.67
KBV: 8.99
PEG-Ratio: 0.36
EV/EBITDA: 13.97
Rentabilität:
Bruttomarge: 65.93%
Gewinnmarge: 28.54%
Operative Marge: 35.94%
Managementeffizenz:
Gesamtkaprendite: 33.36%
Eigenkaprendite: 53.65%
>ORION CORP B Peer Group
 
06.10.26 - 09:18
Orion Pharma, Qilu Partner On Pembrolizumab Biosimilar In Europe (AFX)
 
HELSINKI (dpa-AFX) - Orion Corp. (0M2N.L, ORNAV.HE, ORNBV.HE) and Qilu Pharma Europe have entered into an agreement to commercialise an intravenous (IV) pembrolizumab biosimilar in Europe.Pembroli......
06.10.26 - 08:01
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market (GlobeNewswire EN)
 
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST        ...
05.10.26 - 14:01
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company′s first biologic candidate to reach clinical testing (GlobeNewswire EN)
 
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical testing....
30.09.26 - 08:06
Orion Corporation completed share acquisitions (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE30 SEPTEMBER 2026 at 9.05 EEST        ...
30.09.26 - 08:01
Orion Corporation: Acquisition of own shares during week 40, 2026 (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY'S OWN SHARES30/09/2026 at 09.00 EEST        ...
25.09.26 - 18:02
Orion Corporation: Acquisition of own shares during week 39, 2026 (GlobeNewswire EN)
 
Orion Corporation: Acquisition of own shares during week 39, 2026...
14.08.26 - 19:54
ORION Corp. Reports Higher Revenue And Profit In Q2 2026 (AFX)
 
SEOUL (dpa-AFX) - ORION Corp. (271560.KS) on Friday reported revenue of KRW 893.59 billion for the second quarter of 2026, compared with KRW 777.17 billion in the same period of 2025. For the six ......
17.07.26 - 13:01
ROUNDUP: Orion Q2 Profit Rises; Revises Outlook (AFX)
 
HELSINKI (dpa-AFX) - (Adds Outlook)For the full year, Orion Oyj (0M2N.L) now expects operating profit of EUR 650 million to EUR 750 million, compared with the previous expectation of EUR 600 milli......
17.07.26 - 12:00
Orion Oyj Reveals Advance In Q2 Income (AFX)
 
HELSINKI (dpa-AFX) - Orion Oyj (0M2N.L) reported earnings for its second quarter that Increased, from last yearThe company's bottom line came in at EUR140.2 million, or EUR1 per share. This compar......
17.07.26 - 11:03
Orion Group Half-Year Financial Report January–June 2026 (GlobeNewswire EN)
 
ORION CORPORATION  HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST...
17.07.26 - 09:33
Orion Corporation′s financial reporting and Annual General Meeting in 2027 (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 17 JULY 2026 at 10.30 EEST        ...
15.07.26 - 08:03
45,611 Orion Corporation A shares converted into B shares (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 JULY 2026 at 9.00 EEST        ...
03.07.26 - 08:03
Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026 (GlobeNewswire EN)
 
ORION CORPORATION PRESS RELEASE 3 JULY 2026 at 9.00 EEST        ...
30.06.26 - 07:03
Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market (GlobeNewswire EN)
 
ORION CORPORATION PRESS RELEASE 30 JUNE 2026 at 8.00 EEST        ...
23.06.26 - 08:33
Orion Pharma′s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission (GlobeNewswire EN)
 
ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST         Orion Pharma's ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission...
18.06.26 - 13:03
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS18 June 2026 at 14.00 EEST                       ...
17.06.26 - 15:03
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS17 June 2026 at 16.00 EEST                       ...
16.06.26 - 15:03
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS16 June 2026 at 16.00 EEST                       ...
15.06.26 - 15:18
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS15 June 2026 at 16.15 EEST                       ...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Philosophen verderben die Sprache, Poeten die Logik, und mit dem Menschenverstand kommt man durchs Leben nicht mehr. - Friedrich Johann Christoph Schiller
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!